Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13281
Abstract: Ibrutinib exerts promising anticancer effects in chronic lymphocytic leukaemia (CLL). However, acquired resistance occurs during treatment, necessitating the exploration of underlying mechanisms. Although three‐dimensional genome organization has been identified as a major player in the… read more here.
Keywords: pak1; ibrutinib resistant; chronic lymphocytic; chromosome conformation ... See more keywords
JAK-STAT signaling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular oncology"
DOI: 10.1002/1878-0261.13364
Abstract: Preventing or overcoming resistance to the Bcl‐2 inhibitor venetoclax is an emerging unmet clinical need in patients with chronic lymphocytic leukaemia (CLL). The upregulation of anti‐apoptotic Bcl‐2 members through signalling pathways within the tumor microenvironment… read more here.
Keywords: sensitivity; resistance; cll; jak stat ... See more keywords
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25561
Abstract: In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the… read more here.
Keywords: cll; first line; group; line treatment ... See more keywords
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26127
Abstract: REFERENCES 1. Nader E, Conran N, Romana M, Connes P. Vasculopathy in sickle cell disease: from red blood cell sickling to vascular dysfunction. Compr Physiol. 2009;84(9):618-625. 2. Bernaudin F, Verlhac S, Chevret S, et al.… read more here.
Keywords: cll; alpha; blood; nitric oxide ... See more keywords
Role and timing of new drugs in CLL
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2397
Abstract: Signaling through the B‐cell receptor (BCR) has emerged as a potential key mechanism in CLL pathogenesis. It has been suggested that the BCR may induce antigen‐independent cell‐autonomous signaling in CLL. The importance of BCR signaling… read more here.
Keywords: role timing; timing new; cll; bcr ... See more keywords
CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2437_88
Abstract: in the REMARC study had centralized prospective peripheral blood lymphocyte analyses by flow cytometry (FCM) either at diagnosis (n = 220), at randomization. (n = 188) or both (n = 73). Absolute counts of CD4+,… read more here.
Keywords: cll; group; study; cell count ... See more keywords
PHARMACOKINETIC ANALYSIS AND CLINICAL RESULTS OF THE PHASE 1 DOSE ESCALATION AND EXPANSION CXD101 TRIAL IN RELAPSED, REFRACTORY LYMPHOMA
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2439_186
Abstract: and anemia (12%). The overall response rate (ORR) was 71% (12/17 pts) and median progression‐free survival (PFS) was not estimable across all cohorts; ORR in each subtype was 80% (4/5 pts) in DLBCL with 1… read more here.
Keywords: cll; clinical results; analysis clinical; results phase ... See more keywords
Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2580
Abstract: Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for… read more here.
Keywords: rituximab; cll; study; fludarabine cyclophosphamide ... See more keywords
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2667
Abstract: Ibrutinib, a first‐generation Bruton's tyrosine kinase (BTK) inhibitor, could improve immunity of relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. Whether zanubrutinib, a second‐generation selective BTK inhibitor, has similar effects as ibrutinib… read more here.
Keywords: cll; lymphocytic leukemia; treatment; small lymphocytic ... See more keywords
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.2888
Abstract: In the pathogenesis of chronic lymphocytic leukemia (CLL) the microenvironment plays an important role, as it produces survival signals and mediates drug resistance. Lenalidomide, which has immunomodulatory effect, can enhance the activation of T‐, NK‐cells… read more here.
Keywords: cll; cll cells; lymphocytic leukemia; effect ... See more keywords
SUBCUTANEOUS IMMUNOGLOBULINS IN CHRONIC LYMPHOCYTIC LEUKAEMIA WITH SECONDARY ANTIBODY DEFICIENCY. A MONOCENTRIC EXPERIENCE DURING COVID-19 PANDEMICS.
Sign Up to like & getrecommendations! Published in 2022 at "Hematological oncology"
DOI: 10.1002/hon.2966
Abstract: Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukaemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage,… read more here.
Keywords: cll; secondary antibody; covid; antibody deficiency ... See more keywords